Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of healthy human participants, asthmatic and COPD patients

From: Effects of the common polymorphism in the human aldehyde dehydrogenase 2 (ALDH2) gene on the lung

  Healthy volunteers
(n = 967)
Bronchial asthma
(n = 751)
COPD
(n = 289)
Age (years) 50.0 ± 9.1 57.0 ± 16.8 74.7 ± 8.6
Female (%) 526 (54.4%) 445 (59.3%) 31 (10.6%)
Smoking Index Groupa, b
 0
607 (62.8%) 481 (64.0%) 10 (3.5%)
 1–200 126 (13.0%) 103 (13.7%) 9 (3.1%)
 >200 234 (24.2%) 145 (19.3%) 269 (93.1%)
FVC (L) 3.22 ± 0.76 2.92 ± 0.94 2.65 ± 0.87
FEV1 (L) 2.68 ± 0.64 2.11 ± 1.06 1.25 ± 0.58
Predicted FEV1 (%) 93.3 ± 12.1 85.3 ± 22.7 53.4 ± 22.1
FEV1/FVC (%) 83.2 ± 5.2 71.0 ± 12.4 47.2 ± 12.4
FEV1 decline (mL/year) 23.4 ± 49.3 (n = 742) NA NA
  1. aThe Smoking Index Group is calculated by multiplying the average number of cigarettes smoked per day with the number of years of smoking
  2. bSmoking history was not available for 22 and 1 asthma and COPD patients, respectively